Cyclo Therapeutics, Inc.
NASDAQ:CYTH
Overview | Financials
Company Name | Cyclo Therapeutics, Inc. |
Symbol | CYTH |
Currency | USD |
Price | 0.68 |
Market Cap | 19,457,792 |
Dividend Yield | 0% |
52-week-range | 0.55 - 2.12 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. N. Scott Fine |
Website | https://www.cyclotherapeutics.com |
An error occurred while fetching data.
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD